Cell Biology
Stem Cells
Embryonic, adult, and induced pluripotent stem cells — self-renewing progenitors driving development, tissue repair, and regenerative medicine
Stem cells self-renew (divide to produce more stem cells) and differentiate into specialized cell types. Embryonic stem cells (ESCs) from the inner cell mass of the blastocyst are pluripotent — can form any of the three germ layers' derivatives. Adult (somatic) stem cells are multipotent or unipotent and reside in tissue-specific niches: hematopoietic stem cells in bone marrow, mesenchymal in stroma, neural in subventricular and subgranular zones, intestinal at crypt base. Induced pluripotent stem cells (iPSCs) — Yamanaka 2006 — are reprogrammed from adult somatic cells using OCT4, SOX2, KLF4, c-MYC. Clinical use today: bone marrow transplant for leukemia, corneal limbal stem cells, skin grafts. Trials in Parkinson disease, macular degeneration, type 1 diabetes, spinal cord injury are advancing.
- PluripotentCan form all three germ layers (ESC, iPSC)
- MultipotentRestricted to one lineage (hematopoietic, mesenchymal)
- Yamanaka factorsOCT4, SOX2, KLF4, c-MYC (2006)
- Most established therapyHematopoietic stem cell transplant for leukemia
- Adult stem cell nichesBone marrow, intestinal crypts, hair follicle bulge, neural SVZ/SGZ
- Nobel for iPSCsShinya Yamanaka, 2012
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Why stem cells matter
- Hematology and oncology. Bone marrow transplant cures otherwise lethal leukemias and immunodeficiencies.
- Regenerative medicine. Aim to replace lost neurons (Parkinson), cardiomyocytes (post-MI), beta cells (T1D), photoreceptors (AMD).
- Disease modeling. Patient iPSCs differentiated to affected cell type recreate disease in a dish for drug screening.
- Drug toxicity testing. iPSC-derived cardiomyocytes screen for QT prolongation; hepatocytes for hepatotoxicity.
- Developmental biology. ESCs and organoids reveal pathways of organogenesis impossible to study in vivo.
- Tissue engineering. Scaffolds seeded with stem cells aim to grow replacement organs (trachea, bladder, liver buds).
- Cancer stem cell concept. Subpopulation of tumor cells with self-renewal explains relapse after debulking therapy.
Common misconceptions
- All stem cells are pluripotent. Most adult stem cells are multipotent or unipotent — restricted in fate.
- iPSCs require embryos. iPSCs are reprogrammed from adult cells without any embryonic material.
- Stem cell injections cure orthopedic conditions broadly. Most marketed knee/back injections lack regulatory approval and clinical evidence.
- Embryonic stem cells become any tissue automatically. Differentiation requires precisely staged growth factor cues.
- Stem cells are immortal. They have finite proliferation; long-term culture accumulates mutations.
- Stem cell therapy is universally safe. Teratoma risk, immune rejection, and ectopic differentiation are documented complications.
Frequently asked questions
What's the difference between totipotent, pluripotent, and multipotent?
Totipotent: can form the entire organism plus extraembryonic tissues — only the zygote and first few blastomeres. Pluripotent: can form any cell of the three germ layers but not extraembryonic — ESCs and iPSCs. Multipotent: limited to one lineage — hematopoietic stem cell makes all blood cells; neural stem cell makes neurons, astrocytes, oligodendrocytes. Unipotent: only one cell type — spermatogonia. Potency decreases with development.
How are iPSCs made?
Adult somatic cells (often skin fibroblasts) are infected with vectors expressing OCT4, SOX2, KLF4, and c-MYC. Within 2-4 weeks a small fraction of cells silence somatic genes, activate pluripotency network, and become iPSCs morphologically and molecularly indistinguishable from ESCs. Modern protocols use non-integrating vectors (Sendai virus, mRNA, episomal plasmids) to avoid genome insertion. iPSCs bypass the ethical issues of embryo destruction and allow patient-specific cells for disease modeling and autologous therapy.
How does bone marrow transplant work?
Indications: acute and chronic leukemias, lymphoma, aplastic anemia, hemoglobinopathies, severe combined immunodeficiency. Recipient is conditioned with chemotherapy ± total body irradiation to ablate marrow. Donor HSCs (peripheral blood after G-CSF mobilization, marrow aspirate, or cord blood) are infused; they home to marrow via CXCR4-CXCL12 signaling and engraft within 2-4 weeks. Allogeneic transplants risk graft-versus-host disease but offer graft-versus-leukemia effect. HLA matching is critical.
What are mesenchymal stem cells used for?
MSCs are multipotent stromal cells from bone marrow, adipose, umbilical cord. Differentiate into bone, cartilage, fat, and possibly other mesodermal lineages. Strongly immunomodulatory — secrete anti-inflammatory cytokines and modulate T cells. Approved or in trials for graft-versus-host disease, Crohn fistulas, knee osteoarthritis. Most clinical effects appear paracrine rather than from direct engraftment. Caution: many marketed clinics offer unproven MSC therapies.
What's the niche concept?
Stem cells require a specialized microenvironment — the niche — to maintain self-renewal and prevent differentiation. Bone marrow niche includes osteoblasts, endothelial cells, mesenchymal stromal cells, sympathetic nerve fibers signaling via SCF, CXCL12, angiopoietin. Intestinal niche: Paneth cells in crypts secrete Wnt and Notch ligands. Loss of niche signals drives differentiation; aberrant niche supports cancer stem cells. Engineered niches in vitro support stem cell expansion.
What clinical successes have stem cells achieved?
Hematopoietic stem cell transplant cures leukemias, lymphomas, immunodeficiencies. Corneal limbal stem cell transplants restore vision after chemical burns. Cultured epidermal sheets cover extensive burns. Mesenchymal stem cell therapy for steroid-refractory graft-versus-host disease (Ryoncil approved 2024). RPE cells from ESCs/iPSCs are in trials for macular degeneration with stable visual benefit. Dopaminergic neurons from iPSCs are in early Parkinson disease trials with first patient implants showing graft survival.
What are the risks and limitations?
Tumorigenicity: undifferentiated pluripotent cells form teratomas; even partially differentiated populations can carry residual pluripotent cells. Immune rejection: allogeneic cells trigger rejection unless HLA matched. Functional integration: transplanted neurons must wire correctly. Genetic instability: long-term culture accumulates mutations. Ethical issues: ESC derivation requires embryo destruction (resolved by iPSCs). Unproven commercial clinics offer untested therapies — major patient safety concern.